Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI previously announced that its pivotal PIX 301 EXTEND trial of pixantrone had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14 of 70 patients (20.0%) for the pixantrone arm compared to four of 70 patients (5.7%) for the standard chemotherapy arm, p=0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission while on study.

The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). Although the grade 3, 4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a slightly higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (8.8% vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and tachycardia.

In April 2009, CTI began a rolling submission of a New Drug Application (the "NDA") with the FDA for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of ... be exhibiting and taking orders for this system at ... San Diego Convention Center in ... - 22.  The SP6800 Spectral Analyzer ... into new and novel functionalities for the immunology, oncology, ...
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
(Date:5/17/2013)... PONCE , Puerto Rico , May ... southern, central and western Puerto Rico , ... , PR) Center has improved its radiation therapy capabilities with ... in Puerto Rico . Versa HD offers ... wide range of tumors throughout the body, while also enabling ...
Breaking Medicine Technology:Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2
... 11, 2007 /PRNewswire-FirstCall/ - Paul S.,Aisen, M.D., ... Medical Center, and principal investigator in the ... III clinical trial,for tramiprosate (ALZHEMED(TM)) will present ... for the treatment of,Alzheimer's disease (AD). The ...
... /PRNewswire/ -- Sugammadex -,the novel selective relaxant binding ... business unit of Akzo Nobel -,demonstrated in a ... of neuromuscular blockade as compared to neostigmine,without evidence ... muscle relaxation.(1),(2) The results of this,pivotal Aurora trial ...
Cached Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 3Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 4
(Date:5/20/2013)... 20, 2013 Milpitas, Los Angeles, ... leader in enterprise-class information archiving, eDiscovery and migration ... 7.0, the latest release in the MessageSolution product ... the legal discovery lifecycle. MessageSolution will exhibit at ... CA. , As the first stop of the ...
(Date:5/20/2013)... InVite® Health, a leading nutraceutical firm ... of its new Greens Hx™ product; a ... with plant extracts from 39 super foods including sea ... pectin, plant enzymes and non-dairy probiotics. A small ... levels of several servings of vegetables. The product is ...
(Date:5/20/2013)... May 20, 2013 The transvaginal mesh ... device law firm, report that two important bellwether trials ... in state and federal litigations established for C.R. Bard ... the first C.R. Bard bellwether trial will begin in ... of West Virginia. (In re: C.R. Bard, Inc., ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Today is ... Perfect Interview Answers Webinar tomorrow. Job seekers ... Career Confindential’s expert career coach, will show job seekers ... Webinar attendees will also learn the perfect interview answers ... as interview techniques that will get them hired. Job ...
(Date:5/19/2013)... California has one of the largest pool of ... discovering that comprehensive background checks are playing an important role ... Driving records can paint an accurate portrait of a ... any DUI arrests, speeding offenses, and traffic violations to their ... to experience 4SafeDrivers.com, a new online service which allows users ...
Breaking Medicine News(10 mins):Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 2Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 3Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 4Health News:InVite® Health Introduces New Food-Based Dietary Supplement – Greens Hx™ 2Health News:InVite® Health Introduces New Food-Based Dietary Supplement – Greens Hx™ 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4Health News:Today Is the Last Day to Register for Tomorrow’s Perfect Interview Answers Webinar From Career Confidential 2Health News:4SafeDrivers.com Announces Driving Record Searches for California Employers 2
... ANN ARBOR, Mich.---Apparently your mom had it right when she ... talked dirty. Lying really does create a desire to clean ... study. "The references to ,dirty hands, or ,dirty mouths, ... of moral purity in terms of more concrete experiences with ...
... at the Indiana University Melvin and Bren Simon Cancer ... show that changes in brain tissue can occur in ... of chemotherapy, often referred to as "chemobrain," have been ... the first to use brain imaging to study women ...
... , CHAPEL HILL, N.C. -- A team of UNC ... National Cancer Institute,s Cancer Nanotechnology Platform Partnerships to address ... effective treatments for pancreatic cancer. Wenbin Lin, PhD, ... MD, assistant professor of surgery and pharmacology, are the ...
... between the increase in sales of new antidepressants in recent ... a study based on figures from the Nordic countries, researchers ... that increased sales of the new medicines could be linked ... find any relationship between reduced sales of the older and ...
... UN Millennium Development Goals (MDG) summit in New York ... the eight goals agreed in 2000 on alleviating world ... to a close, governments, businesses and aid organisations made ... emphasis on improving maternal and child health. A global ...
... Reporter , TUESDAY, Sept. 28 (HealthDay News) -- Think recess, ... break in the school day set aside for running and ... adult life. What if your workplace started offering recess on ... a good idea but possibly one of the most solid ...
Cached Medicine News:Health News:Dirty hands, dirty mouths: U-M study finds a need to clean the body part that lies 2Health News:IU researchers: Chemotherapy alters brain tissue in breast cancer patients 2Health News:Decrease in suicide not linked to newer antidepressants 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 3Health News:Adding Recess to the Workday Gains Backers 2Health News:Adding Recess to the Workday Gains Backers 3Health News:Adding Recess to the Workday Gains Backers 4
The entirely open modular system is especially suitable for stereotactic microsurgical procedures....
Used to negotiate tortuous vessels....
The Emerald Guidewire is intended for percutaneous introduction of catheters....
... The MULTI-LINK VISION Coronary Stent System is ... cobalt chromium stents. Cobalt chromium is stronger ... a cobalt chromium stent can have similar ... steel stent with struts that are only ...
Medicine Products: